Subject:
- Active Substance: Venetoclax
- Name: Venclyxto
- Therapeutic area: Acute myeloid leukaemia (AML)
- Pharmaceutical company: AbbVie GmbH & Co. KG
Time table:
- Publication of project plan: 28.04.2021
- Publication of final assessment: 08.07.2021 (revised 03.09.2021)
Assessment information:
- Title: Venetoclax with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy
- Author/Co-Author: NOMA (Norway), JAZMP (Slovenia)
- Dedicated Reviewers: AEMPS (Spain), NIPHNO (Norway), MoH (Ukraine), SMCA (Lithuania)